证券代码：600420 证券简称：国药现代 公告编号：2025-072 上海现代制药股份有限公司 2025年第二次临时股东会决议公告 (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (一)股东会召开的时间：2025 年 9 月 15 日 (二)股东会召开的地点：上海市浦东新区建陆路 378 号 B1 楼五层会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 422 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 772,689,759 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的 | 57.6129 | | 比例（%） | | 一、会议召开和出席情况 本次股东会由公司董事会召集，公司董事长许继辉先生主持。会议的召集、 召开程序符合国家有关法律、法规和《公司章程》的规定。 (五)公司董 ...

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. is actively engaging with investors through a performance briefing and has received regulatory approvals for its products, indicating a focus on transparency and growth in the pharmaceutical sector [2][9][14]. Group 1: Investor Engagement - The company will participate in the 2025 Shanghai Stock Exchange collective reception day and mid-year performance briefing on September 19, 2025, to address investor concerns [2][3]. - Investors can submit questions before the event via a dedicated webpage, and the company will respond to commonly raised issues during the briefing [2][3][4]. - The event will be held online from 15:00 to 17:00 on September 19, 2025, allowing for interactive communication [4][5]. Group 2: Product Approvals - The company's subsidiary, Sinopharm Group Rongsheng Pharmaceutical Co., Ltd., received approval for a supplementary application for sodium bicarbonate injection, which includes a new specification and has passed the consistency evaluation for generic drugs [9][10]. - The sodium bicarbonate injection is indicated for treating metabolic acidosis and preventing uric acid kidney stones, with a reported sales figure of approximately RMB 580 million in 2024 [11]. - The company has invested about RMB 2.7442 million in the research and development of the sodium bicarbonate injection's consistency evaluation [11]. Group 3: GMP Compliance - Sinopharm Group Weiqida Pharmaceutical Co., Ltd., another subsidiary, has passed the GMP compliance inspection for its raw material production lines, which is crucial for maintaining product quality [14][15]. - The inspection covered the production of acarbose, a drug used for diabetes treatment, and the facility has undergone significant renovations with an investment of approximately RMB 22.7604 million [15]. - This compliance is expected to enhance the company's product offerings and maintain stable production capabilities [16].

Group 1 - The core point of the article is that China National Pharmaceutical Group Modern has announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a supplemental drug application, allowing for an increase in the specifications of sodium bicarbonate injection and passing the consistency evaluation of generic drug quality and efficacy [2] Group 2 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio and potentially increasing market competitiveness [2] - The sodium bicarbonate injection is expected to meet the growing demand in the pharmaceutical market, reflecting the company's commitment to quality and efficacy in its offerings [2]

（文章来源：证券日报） 证券日报网讯 9月12日晚间，国药现代发布公告称，近日，公司全资子公司国药集团威奇达药业有限公 司（以下简称国药威奇达）收到药品GMP符合性检查告知书，国药威奇达的108车间、综合原料药车间 相关生产线通过GMP符合性检查。 ...

Group 1 - The core point of the article is that China National Pharmaceutical Group Modern stated that Guoyao Ruifulai Pharmaceutical Co., Ltd. is a subsidiary of China Medical Investment Co., Ltd. and is not under the control of China National Pharmaceutical Group [2] - The company emphasized that all significant information will be disclosed through announcements in designated media [2]

Group 1 - The company, China National Pharmaceutical Group Modern (国药现代), is currently in the negotiation phase for external research and development collaborations [1] - The company has received clinical approval for two modified new drugs: one is Brivaracetam oral film, primarily used for the treatment of mental disorders and as an adjunct therapy for depression; the other is Topiroxostat tablets, a new uric acid-lowering product, which is an iterative product of Febuxostat [1]

Group 1 - Yishitong plans to repurchase shares worth between 30 million to 55 million yuan at a price not exceeding 40.69 yuan per share, intended for employee stock ownership plans or equity incentives [1] - Guoyao Modern's subsidiary has received approval for a sodium bicarbonate injection to increase specifications and pass consistency evaluation [2] - Xinjing plans to reduce its shareholding by up to 1.2 million shares, accounting for 0.78% of the total share capital, between October 14, 2025, and January 13, 2026 [2] Group 2 - Jinfeikeda intends to apply for an additional credit limit of up to 60 million yuan from Jiangsu Financial Leasing [3] - Boshi Co. signed a project contract worth 235 million yuan with Guoneng Yulin Chemical for a three-year service period starting from October 31, 2025 [4] - Luan Energy reported a coal sales volume of 3.78 million tons in August, a decrease of 13.70% year-on-year [6] Group 3 - Shengnong Development achieved sales revenue of 1.857 billion yuan in August, a year-on-year increase of 19.11% [8] - Huading Co. plans to transfer 9.26% of its shares through public solicitation of transferees [10] - China Metallurgical Group's new contract amount from January to August decreased by 18.2% year-on-year, totaling 679.57 billion yuan [12] Group 4 - Longjing Environmental plans to invest approximately 3.99 billion yuan in the construction of a hydropower station project in the Democratic Republic of the Congo [14] - Longjing Environmental also plans to invest 2.391 billion yuan in an integrated energy station project, expected to be operational by the second quarter of 2026 [15] - Transsion Holdings has set the transfer price for its shares at 81.81 yuan per share, with a subscription rate of 1.15 times [17] Group 5 - Sinopec Oilfield Services won a bid for a natural gas pipeline project with a contract value of 858 million yuan [18] - Huaitian Thermal Power received a warning letter from the Liaoning Securities Regulatory Bureau for information disclosure violations [20] - China Nuclear Engineering signed new contracts totaling 96.633 billion yuan as of August [22] Group 6 - Shanghai Mechanical plans to publicly transfer 67% of its stake in Simic Welding Materials, with an estimated value of 291 million yuan [24] - Zhongke Environmental appointed Tang Xia as the new deputy general manager [26] - Baiyang Pharmaceutical signed a strategic cooperation agreement with Jikun Pharmaceutical for a drug project [28] Group 7 - Jinsong New Materials received a warning letter from the Zhejiang Securities Regulatory Bureau for fundraising irregularities [27] - Weitang Industrial obtained a national invention patent for a battery tray welding deformation control device [29] - Dongsoft Carrier secured two national invention patents related to energy management and voltage regulation circuits [30] Group 8 - Lian De Equipment won a bid for the BOE AMOLED production line project with a total amount of 201 million yuan [31] - Jingjiawei signed a strategic cooperation agreement with Anchaoyun to develop high-performance cloud desktop solutions [32] - Chuaning Biological received approval for a 1 billion yuan medium-term note registration [34] Group 9 - Jifeng Co. plans to reduce its shareholding by up to 2% through block trading [36] - Taihe Intelligent plans to transfer 5.79% of its shares to Sunshine New Energy Development Co., Ltd. [36] - Yangmei Chemical will change its stock name to "Luhua Technology" starting September 17, 2025 [38] Group 10 - ST Songfa's subsidiary signed contracts for the construction of four container ships, with a total value of approximately 300 to 500 million USD [40] - Green Energy Huichong plans to establish a joint venture with Xianyang Economic Development Group with a registered capital of 250 million yuan [42] - Baiyao Tai received a milestone payment of 5.4 million USD from Intas Pharmaceuticals [38]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (国药容生), received approval from the National Medical Products Administration for a supplementary application regarding sodium bicarbonate injection, which has now passed the consistency evaluation for generic drug quality and efficacy [1] Group 1 - The approved sodium bicarbonate injection will have an increased specification and has been granted a drug approval number [1] - Sodium bicarbonate injection is classified as an antacid and is indicated for the treatment of metabolic acidosis [1] - The injection is also used for the prevention of uric acid kidney stones, to reduce the nephrotoxicity of sulfonamide drugs, and to prevent hemoglobin deposition in renal tubules during acute hemolysis [1] Group 2 - Additionally, sodium bicarbonate injection has non-specific therapeutic effects for certain drug poisonings, such as barbiturates, salicylates, and methanol [1]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (600420.SH), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a supplemental application regarding sodium bicarbonate injection, which includes an increase in specifications and has passed the consistency evaluation for generic drug quality and efficacy [1]. Group 1 - The sodium bicarbonate injection is classified as an antacid [1]. - Indications for sodium bicarbonate injection include: (1) treatment of metabolic acidosis; (2) prevention of uric acid kidney stones, reduction of nephrotoxicity from sulfonamides, and prevention of hemoglobin deposition in renal tubules during acute hemolysis; (3) intravenous infusion for non-specific treatment of certain drug poisonings, such as barbiturates, salicylates, and methanol [1].

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd. (国药威奇达), has received a notice of compliance for Good Manufacturing Practice (GMP) inspection, indicating that the production lines in Workshop 108 and the comprehensive raw material pharmaceutical workshop have passed the GMP compliance check [1] Group 1 - The subsidiary, China National Pharmaceutical Group Weichida, has successfully passed the GMP compliance inspection [1] - The inspection covers specific production lines in Workshop 108 and the comprehensive raw material pharmaceutical workshop [1]